Glipizide and metformin both lower A1C by about 1 to 1.5 percent and both cost just a few dollars a month. But the two drugs work on different parts of glucose metabolism and have very different side-effect profiles. Metformin reduces hepatic glucose output and improves insulin sensitivity — without causing hypoglycemia or weight gain. Glipizide stimulates pancreatic insulin release, which lowers blood sugar effectively but causes 2 to 5 kg of weight gain and frequent hypoglycemia. For most adults with type 2 diabetes, metformin is preferred first-line. Glipizide is generally a cost-conscious add-on or second-line option.
Quick Comparison
| Feature | Metformin | Glipizide |
|---|---|---|
| Drug class | Biguanide | Sulfonylurea (2nd gen) |
| Main action | Reduces liver glucose output, improves muscle insulin sensitivity | Stimulates pancreatic insulin release |
| A1C drop | 1.0 to 1.5% | 1.0 to 1.5% |
| Weight | Neutral or modest loss | +2 to 5 kg |
| Hypoglycemia (alone) | None | Common |
| Cardiovascular safety | Possibly modest benefit | Neutral; UKPDS overall favorable |
| Renal use | Avoid <30 mL/min eGFR | Cautious in CKD; preferred SU in mild CKD |
| Major side effects | GI upset, B12 deficiency | Hypoglycemia, weight gain |
| Pregnancy | Increasingly used (with caution) | Not used (insulin preferred) |
| Generic status | Yes | Yes |
| Cost/month | ~$4 | $4 to $15 |
How Each Drug Works
Metformin primarily reduces gluconeogenesis — the process by which the liver makes new glucose. It also modestly improves how skeletal muscle responds to insulin. It does not stimulate the pancreas to make more insulin. Because of that mechanism, metformin lowers fasting glucose effectively and does not cause hypoglycemia on its own.
Glipizide binds the SUR1 receptor on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering insulin secretion. The stimulation is largely glucose-independent — the pancreas releases insulin whether glucose is high or normal — which is why hypoglycemia is the dominant risk.
A1C and Glucose Effects
- Metformin: 1.0 to 1.5 percent A1C reduction; 30 to 60 mg/dL fasting glucose reduction. Onset of effect builds over 2 to 4 weeks.
- Glipizide: 1.0 to 1.5 percent A1C reduction; 30 to 60 mg/dL fasting glucose reduction. Acute glucose-lowering effect within 30 minutes of a dose.
- Combination: roughly 1.5 to 2.5 percent A1C reduction because the mechanisms are additive.
Side Effect Profiles Compared
| Side Effect | Metformin | Glipizide |
|---|---|---|
| Hypoglycemia (alone) | Rare | Common |
| Weight gain | None — often modest loss | +2 to 5 kg |
| GI upset | Nausea, diarrhea, gas (20 to 30% initially) | Mild upset uncommon |
| B12 deficiency | Yes — check periodically | No |
| Lactic acidosis | Very rare; risk rises in CKD or acute illness | Not associated |
| Allergic skin reaction | Very rare | Rare (sulfa-class) |
| Cardiovascular safety | Possibly modest benefit (UKPDS subgroup) | Neutral overall |
Cardiovascular and Long-Term Outcomes
The UK Prospective Diabetes Study (UKPDS) followed more than 4,000 newly diagnosed type 2 diabetes patients for 10 years. Intensive glucose control with sulfonylureas (mostly glyburide and chlorpropamide) or insulin reduced microvascular complications such as retinopathy and nephropathy. A subgroup of overweight patients randomized to metformin saw additional reductions in macrovascular endpoints — a finding that helped establish metformin as preferred first-line therapy. Modern ADA guidance reflects this history and updated evidence on the newer drug classes such as GLP-1 agonists and SGLT2 inhibitors.
Use in Special Populations
- Older adults: Metformin is generally well tolerated; glipizide requires caution and the lower end of the dose range. Glyburide is to be avoided in this group; glipizide is the preferred sulfonylurea if one must be used.
- Kidney disease: Metformin contraindicated below 30 mL/min eGFR; reduced dose at 30 to 44. Glipizide does not directly harm the kidneys but produces more hypoglycemia as eGFR falls.
- Liver disease: Both drugs require caution in significant liver disease.
- Heart failure: Metformin is generally safe; sulfonylureas are not preferred when SGLT2 inhibitors are accessible because of HF benefit.
- Pregnancy: Metformin can be used with obstetric guidance; sulfonylureas largely replaced by insulin in modern practice.
Practical Decision-Making
For most adults newly diagnosed with type 2 diabetes:
- Metformin is first-line, alongside lifestyle change
- If A1C remains above target, the next step depends on cost and comorbidities
- With cardiovascular disease, heart failure, or CKD — add a GLP-1 agonist or SGLT2 inhibitor
- Without those indications and when cost is the limiting factor — add a sulfonylurea (glipizide preferred), DPP-4 inhibitor, or pioglitazone
- Glipizide is rarely the right first choice when metformin is tolerated, because of weight and hypoglycemia trade-offs
Monitoring Each Drug
| Test | Metformin | Glipizide |
|---|---|---|
| A1C | Every 3 to 6 months | Every 3 to 6 months |
| Kidney function | At baseline, then yearly | At baseline, then yearly |
| B12 | Every 1 to 2 years if on long-term use | Not needed |
| Liver function | At baseline | At baseline |
| Glucose self-monitoring | Not required if on monotherapy | Often useful, particularly during titration |
Cost Comparison
Both drugs are among the cheapest in the diabetes formulary.
- Metformin generic: ~$4 per month at most pharmacies
- Glipizide generic: $4 to $15 per month
- Fixed-dose combinations (glipizide-metformin) are also available but rarely cheaper than the two generics separately
For comparison, GLP-1 agonists and SGLT2 inhibitors typically cost $500 to $1,300 per month without insurance.
Where Each Drug Fits in 2024 Guidelines
The ADA Standards of Care 2024 recommend metformin as preferred first-line therapy for most adults with type 2 diabetes, alongside lifestyle changes. Glipizide and other sulfonylureas have been pushed later in the algorithm — primarily for cost-constrained patients or when newer drug classes are inaccessible. Patients with cardiovascular disease, heart failure, or chronic kidney disease should preferentially receive a GLP-1 agonist or SGLT2 inhibitor early, sometimes alongside metformin.
Related Reading
See our deeper guides on glipizide, the broader sulfonylureas list, and sulfonylureas side effects. The A1C levels guide and broader treatment overview add context on goal-setting.
The Bottom Line
Metformin and glipizide both work — both lower A1C by 1 to 1.5 percent at low cost. The difference is in the trade-offs. Metformin does not cause weight gain or hypoglycemia and has a long safety record; the main downside is GI upset and the slow accrual of vitamin B12 deficiency in long-term use. Glipizide is equally effective at glucose lowering but causes 2 to 5 kg of weight gain and real hypoglycemia, particularly in older adults, kidney disease, irregular meals, and alcohol use. ADA 2024 places metformin first; glipizide is a cost-conscious add-on or second-line option. Talk to your clinician about which combination, if any, fits your specific situation.
